Plavix, UK

Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 30 April 2018

Indication(s)

Prevention of atherothrombotic events
Clopidogrel is indicated in:
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
• Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Anticoagulation Therapy for Stroke Prevention

Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

More information

Category	Value
Agency product number	EMEA/H/C/000174
Orphan designation	No
Date First Approved	15-07-1998
Type	Medicinal product subject to medical prescription
Marketing authorisation holder	Sanofi Clir SNC

Data available by region

Region	Name
Italia	Plavix (Clopidogrel)
Nederland	Plavix (Clopidogrel)
France	Plavix (Clopidogrel)
Deutschland	Plavix (Clopidogrel)
España	Plavix (Clopidogrel)
United Kingdom	Plavix (Clopidogrel)
Norway	Plavix (Klopidogrel)
Portugal	Plavix (Clopidogrel)
Sverige	Plavix (Klopidogrel)
United States	Plavix (CLOPIDOGREL BISULFATE)

Alternatively login via

Google +

A

C

D

E

G

H

I

M

N

O

P

R

S

T

U

A

C

D

H

I

L

M

N

O

P

R

A

B

C

Learning Zones in English